Edit
Eureka Therapeutics.
http://www.eurekainc.com/Last activity: 24.01.2018
Active - Reference to Eureka Therapeutics, Inc
Employees: 51-200
Total raised: $60M
Investors 1
| Date | Name | Website |
| - | Acorn Camp... | acorncampu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.01.2018 | Series D | $60M | - |
Mentions in press and media 5
| Date | Title | Description |
| 24.01.2018 | Term Sheet — Wednesday, January 24 | 5 Qs WITH A DEALMAKER Four years ago, Arlan Hamilton was living out of a hotel room that she shared with her mom. At that point, she had given up a career as a live music production coordinator to become a venture capitalist. There were a f... |
| 23.01.2018 | Eureka Therapeutics Closes $60M Series D Financing | Eureka Therapeutics, Inc., an Emeryville, CA-based clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, completed a $60m Se... |
| 23.09.2014 | Startup gets $21M for monoclonal antibody that reaches inside the cancer cell | About 90 percent of cancer-specific targets are intracellular proteins, Eureka says, but traditional monoclonal antibodies in humans have only been able to target proteins found on the outside of cancer cells. The company continues: Because... |
| 17.11.2008 | Eureka strikes $6M for cancer antibodies | Drug developer Eureka Therapeutics brought in $6 million in second-round financing to continue development of antibodies used to treat cancer, VentureWire reports. Harbinger Venture Management led the round, with contributions coming from A... |
| - | Startup gets $21M for monoclonal antibody that reaches inside the cancer cell | Most human monoclonal antibody therapies target proteins on the outer membrane of the cell – but a Bay Area startup is receiving a healthy flush of cash to further investigate its drug that reaches cancer cells on the inside. Cancer immunot... |